0000000000568065

AUTHOR

Erhan Ayhan

0000-0003-1416-2636

showing 3 related works from this author

Low dose of isotretinoin: A comprehensive review

2020

Isotretinoin is a first-generation retinoid initially approved for the treatment of severe cases of acne vulgaris (nodulocystic acne). Because of its broad anti-inflammatory and immunomodulatory properties, it has been used beyond its initial approval in a myriad of other indications. Adverse effects of isotretinoin vary from xerosis to teratogenicity. Herein, we reviewed the literature, through date-unlimited PubMed search, from inception till December 2019, using the following search terms: "low-dose isotretinoin" and "dermatology," "isotretinoin and safety," "isotretinoin, off-label uses," "isotretinoin and male fertility," "isotretinoin, iPLEDGE system," aiming to deliver a therapeutic …

Malemedicine.medical_specialtyNodulocystic acneDermatologyRetinoids030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineAcne VulgarismedicineHumansIsotretinoinskin and connective tissue diseasesAdverse effectIsotretinoinAcnebusiness.industryLow doseGeneral Medicinemedicine.diseaseDermatologyClinical PracticeSafety profileSearch terms030220 oncology & carcinogenesisDermatologic Agentsbusinessmedicine.drugDermatologic Therapy
researchProduct

Systemic isotretinoin therapy in the era of COVID‐19

2020

LetterCoronavirus disease 2019 (COVID-19)Pneumonia ViralMEDLINEComorbidityDermatologyIsotretinoin therapyBetacoronavirusPandemicAcne VulgarismedicineHumansLettersIsotretinoinPandemicsbiologyViral Epidemiologybusiness.industrySARS-CoV-2COVID-19General Medicinebiology.organism_classificationmedicine.diseaseVirologyComorbidityPneumoniabusinessCoronavirus InfectionsBetacoronavirusDermatologic Therapy
researchProduct

Could isotretinoin be a protective agent against COVID-19?: A dermatologist perspective.

2021

Being a "trending" unique treatment for moderate-to-severe acne, isotretinoin (13-cis retinoic acid) (ISO) is currently considered by experts the first line treatment even for mild acne, unless there is an absolute contraindication. ISO was identified, among other retinoids, to inhibit SARS-CoV-2 replication in Vero E6 cells. Shoemark et al.1.

medicine.medical_specialtyskinCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Retinoic acidDermatologyProtective Agents030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCOVID‐19Acne VulgarismedicineHumansskin and connective tissue diseasesLetters to the EditorIsotretinoinContraindicationAcnebusiness.industrySARS-CoV-2COVID-19isotretinoinmedicine.diseaseDermatologyFirst line treatmentchemistry030220 oncology & carcinogenesisVero cellbusinessmedicine.drugDermatologistsJournal of cosmetic dermatology
researchProduct